Wenge Liu

Wenge Liu

Auto-generated profile, based on publicly available information

Wenge Liu


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2006 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
MDMatthew R. Dreher
Matthew R. Dreher
WLWenge Liu
Wenge Liu
CMCharles R. Michelich
Charles R. Michelich
MDMark W. Dewhirst
Mark W. Dewhirst
FYFan Yuan
Fan Yuan
ACAshutosh Chilkoti
Ashutosh Chilkoti
Background: Delivery of anticancer therapeutic agents to solid tumors is problematic. Macromolecular drug carriers are an attractive alternative drug delivery method because they appear to target tumors and have limited toxicity in normal tissues. We investigated how molecular weight influences the accumulation of a model macromolecular drug carrier, dextran covalently linked to a fluorophore, in tumors. Methods: We used dextrans with molecular weights from 3.3 kDa to 2 MDa. Vascular permeability, accumulation, and three-dimensional penetration of these dextrans were simultaneously measured in solid tumors via a dorsal skin fold window chamber, intravital laser-scanning confocal microscopy, and custom image analysis. Results: Increasing the molecular weight of dextran statistically significantly reduced its vascular permeability by approximately two orders of magnitude (i.e., from 154 × 10 −7 cm/s, 95% confidence interval [CI] = 134 to 174 × 10 −7 cm/s, for 3.3-kDa dextran to 1.7 × 10 −7 cm/s, 95% CI = 0.7 to 2.6 × 10 −7 cm/s for 2-MDa dextran; P <.001, two-sided Kruskal–Wallis test) but increased its plasma half-life, which provided ample time for extravasation (i.e., to enter tumor tissue from the vasculature). Tumor accumulation was maximal for dextrans with molecular weights between 40 and 70 kDa. Dextrans of 3.3 and 10 kDa penetrated deeply (greater than 35 μm) and homogeneously into tumor tissue from the vessel wall. After a 30-minute period, a high concentration was observed only approximately 15 μm from the vessel wall for 40- to 70-kDa dextrans and only 5 μm for 2-MDa dextrans. Conclusions: Increasing the molecular weight of dextran statistically significantly reduced its tumor vascular permeability. Dextrans of 40 and 70 kDa had the highest accumulation in solid tumors but were largely concentrated near the vascular surface.

8 November 2009 in Nature Materials
Verified
Journal Article
Open access
PDF file
JMJ. Andrew MacKay
J. Andrew MacKay
MCMingnan Chen
Mingnan Chen
JMJonathan R. McDaniel
Jonathan R. McDaniel
WLWenge Liu
Wenge Liu
ASAndrew J. Simnick
Andrew J. Simnick
ACAshutosh Chilkoti
Ashutosh Chilkoti
New strategies to self-assemble biocompatible materials into nanoscale, drug-loaded packages with improved therapeutic efficacy are needed for nanomedicine. To address this need, we developed artificial recombinant chimeric polypeptides (CPs) that spontaneously self-assemble into sub-100-nm-sized, near-monodisperse nanoparticles on conjugation of diverse hydrophobic molecules, including chemotherapeutics. These CPs consist of a biodegradable polypeptide that is attached to a short Cys-rich segment. Covalent modification of the Cys residues with a structurally diverse set of hydrophobic small molecules, including chemotherapeutics, leads to spontaneous formation of nanoparticles over a range of CP compositions and molecular weights. When used to deliver chemotherapeutics to a murine cancer model, CP nanoparticles have a fourfold higher maximum tolerated dose than free drug, and induce nearly complete tumour regression after a single dose. This simple strategy can promote co-assembly of drugs, imaging agents and targeting moieties into multifunctional nanomedicines.

1 October 2006 in Journal of Controlled Release
Verified
Journal Article
Closed access
HBHelawe Betre
Helawe Betre
WLWenge Liu
Wenge Liu
MZMichael R. Zalutsky
Michael R. Zalutsky
ACAshutosh Chilkoti
Ashutosh Chilkoti
VKVirginia B. Kraus
Virginia B. Kraus
LSLori A. Setton
Lori A. Setton

8 September 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
WGWeiping Gao
Weiping Gao
WLWenge Liu
Wenge Liu
JMJ. Andrew Mackay
J. Andrew Mackay
MZMichael R. Zalutsky
Michael R. Zalutsky
ETEric J. Toone
Eric J. Toone
ACAshutosh Chilkoti
Ashutosh Chilkoti
The challenge in the synthesis of protein-polymer conjugates for biological applications is to synthesize a stoichiometric (typically 1:1) conjugate of the protein with a monodisperse polymer, with good retention of protein activity, significantly improved pharmacokinetics and increased bioavailability, and hence improved in vivo efficacy. Here we demonstrate, using myoglobin as an example, a general route to grow a PEG-like polymer, poly(oligo(ethylene glycol) methyl ether methacrylate) [poly(OEGMA)], with low polydispersity and high yield, solely from the N-terminus of the protein by in situ atom transfer radical polymerization (ATRP) under aqueous conditions, to yield a site-specific (N-terminal) and stoichiometric conjugate (1:1). Notably, the myoglobin-poly(OEGMA) conjugate [hydrodynamic radius (R h ): 13 nm] showed a 41-fold increase in its blood exposure compared to the protein (R h : 1.7 nm) after IV administration to mice, thereby demonstrating that comb polymers that present short oligo(ethylene glycol) side chains are a class of PEG-like polymers that can significantly improve the pharmacological properties of proteins. We believe that this approach to the synthesis of N-terminal protein conjugates of poly(OEGMA) may be applicable to a large subset of protein and peptide drugs, and thereby provide a general methodology for improvement of their pharmacological profiles.

21 September 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WGWeiping Gao
Weiping Gao
WLWenge Liu
Wenge Liu
TCTrine Christensen
Trine Christensen
MZMichael R. Zalutsky
Michael R. Zalutsky
ACAshutosh Chilkoti
Ashutosh Chilkoti
This paper reports a general in situ method to grow a polymer conjugate solely from the C terminus of a recombinant protein. GFP was fused at its C terminus with an intein; cleavage of the intein provided a unique thioester moiety at the C terminus of GFP that was used to install an atom transfer radical polymerization (ATRP) initiator. Subsequent in situ ATRP of oligo(ethylene glycol) methyl ether methacrylate (OEGMA) yielded a site-specific (C-terminal) and stoichiometric conjugate with high yield and good retention of protein activity. A GFP-C-poly(OEGMA) conjugate (hydrodynamic radius ( R h ): 21 nm) showed a 15-fold increase in its blood exposure compared to the protein ( R h : 3.0 nm) after intravenous administration to mice. This conjugate also showed a 50-fold increase in tumor accumulation, 24 h after intravenous administration to tumor-bearing mice, compared to the unmodified protein. This approach for in situ C-terminal polymer modification of a recombinant protein is applicable to a large subset of recombinant protein and peptide drugs and provides a general methodology for improvement of their pharmacological profiles.

1 November 2006 in Journal of Controlled Release
Verified
Journal Article
Closed access
WLWenge Liu
Wenge Liu
MDMatthew R. Dreher
Matthew R. Dreher
DFDarin Y. Furgeson
Darin Y. Furgeson
KPKatia V. Peixoto
Katia V. Peixoto
HYHong Yuan
Hong Yuan
ACAshutosh Chilkoti
Ashutosh Chilkoti